These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 31496438)

  • 1. The Mild and Rapidly Improving Stroke Study (MaRISS): Rationale and design.
    Romano JG; Gardener H; Campo-Bustillo I; Khan Y; Riley N; Tai S; Sacco RL; Khatri P; Smith EE; Schwamm LH
    Int J Stroke; 2019 Dec; 14(9):983-986. PubMed ID: 31496438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Outcomes in Patients With Mild Ischemic Stroke Symptoms: MaRISS.
    Romano JG; Gardener H; Campo-Bustillo I; Khan Y; Tai S; Riley N; Smith EE; Sacco RL; Khatri P; Alger HM; Mac Grory B; Gulati D; Sangha NS; Craig JM; Olds KE; Benesch CG; Kelly AG; Brehaut SS; Kansara AC; Schwamm LH;
    Stroke; 2021 Jun; 52(6):1995-2004. PubMed ID: 33947209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolysis in Mild Stroke: A Comparative Analysis of the PRISMS and MaRISS Studies.
    Asdaghi N; Romano JG; Gardener H; Campo-Bustillo I; Purdon B; Khan YM; Gulati D; Broderick JP; Schwamm LH; Smith EE; Saver JL; Sacco R; Khatri P
    Stroke; 2021 Oct; 52(10):e586-e589. PubMed ID: 34496619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety assessment of alteplase in the treatment of stroke - gender differences.
    Lasek-Bal A; Puz P; Kazibutowska Z
    Neurol Res; 2014 Sep; 36(9):851-6. PubMed ID: 24620981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining mild stroke: outcomes analysis of treated and untreated mild stroke patients.
    Spokoyny I; Raman R; Ernstrom K; Khatri P; Meyer DM; Hemmen TM; Meyer BC
    J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1276-81. PubMed ID: 25906938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of Collaterals is Associated with Larger Infarct Volume and Worse Outcome in Patients with Large Vessel Occlusion and Mild Symptoms.
    Kimmel ER; Al Kasab S; Harvey JB; Bathla G; Ortega-Gutierrez S; Toth G; Jaksich EM; Sheharyar A; Roa J; Hasan DM; Samaniego EA
    J Stroke Cerebrovasc Dis; 2019 Jul; 28(7):1987-1992. PubMed ID: 31036341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presenting Symptoms and Dysphagia Screen Predict Outcome in Mild and Rapidly Improving Acute Ischemic Stroke Patients.
    Gadodia G; Rizk N; Camp D; Bryant K; Zimmerman S; Brasher C; Connelly K; Dunn J; Frankel M; Ido MS; Lugtu J; Nahab F
    J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2876-2881. PubMed ID: 27622864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Even Faster Door-to-Alteplase Times and Associated Outcomes in Acute Ischemic Stroke.
    Jung S; Rosini JM; Nomura JT; Caplan RJ; Raser-Schramm J
    J Stroke Cerebrovasc Dis; 2019 Dec; 28(12):104329. PubMed ID: 31607439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Intravenous Thrombolytic Therapy in Patients With Acute Posterior Circulation Stroke: A Single-Center Study.
    Zhu X; Wang N; Lin H; Zhang P; Chen L; Zhang M; Deng B; Wu T
    J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104537. PubMed ID: 31806454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
    Lorenzano S; Toni D;
    Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND.
    Amiri H; Bluhmki E; Bendszus M; Eschenfelder CC; Donnan GA; Leys D; Molina C; Ringleb PA; Schellinger PD; Schwab S; Toni D; Wahlgren N; Hacke W
    Int J Stroke; 2016 Feb; 11(2):260-7. PubMed ID: 26783318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Stroke Patients With Mild-to-Moderate Pre-existing Disability Should Be Considered for Thrombolysis Treatment.
    Zhang W; Coote S; Frost T; Dewey HM; Choi PMC
    J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2707-2711. PubMed ID: 30037650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors enhancing activities of daily living after stroke in specialized rehabilitation: an observational multicenter study within the Sunnaas International Network.
    Langhammer B; Sunnerhagen KS; Lundgren-Nilsson Å; Sällström S; Becker F; Stanghelle JK
    Eur J Phys Rehabil Med; 2017 Oct; 53(5):725-734. PubMed ID: 28417611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.